osinophilic esophagitis (EoE) is a chronic, immune-mediated disorder affecting the esophagus. It has been reported from all parts of the world, and has been studied mainly in Western countries. 1 Since the initial description, and as a rare entity only approximately 2 decades ago, the burden of EoE has increased substantially. Recent epidemiologic estimates have indicated that 56.7 in 100,000 individuals in the United States are affected by EoE, and this prevalence is comparable with that of inflammatory bowel disease. 2, 3 The incidence of EoE is approximately 1 in 10,000 per year independent of the revisions in diagnostic criteria, changing endoscopy rates, and biopsy practices. 4 Looking forward, with an ongoing increase in the occurrence of food and environmental allergies in developed countries, the incidence and prevalence of EoE is expected to increase, particularly in the pediatric population. 5 EoE has been reported in all ages, and is one of the common causes of feeding dysfunction in children and of esophageal food impaction in adults. It is considered one of the most common chronic gastrointestinal diseases in children that tracks into adulthood. 6 Our understanding of the mechanisms involved in the development of EoE is incomplete. Accumulating evidence from animal model studies, patient cohorts, and application of cutting-edge technologies indicate that in genetically susceptible individuals a combination of factors, including alterations in the esophageal epithelial barrier, provides a conducive environment for antigen presentation to the host immune system. 7 The antigen exposure induces a type 2 helper T-cell response resulting in release of cytokines such as interleukin (IL)5 and IL13. These cytokines stimulate expression of eotaxin-3, a potent eosinophil chemoattractant, in the esophageal epithelium with abnormal recruitment of eosinophils into the esophagus, which typically is devoid of eosinophils.
Eosinophil granular proteins such as major basic protein (MBP)1 and MBP2, eosinophil peroxidase (EPO), eosinophil-derived neurotoxin (EDN), and eosinophil cationic protein are released once the eosinophils degranulate and result in injury to the esophageal epithelium. 8 A delay in the diagnosis of EoE or prolonged and/or uncontrolled eosinophilic inflammation can lead to esophageal remodeling characterized by basal cell hyperplasia, subepithelial fibrosis, angiogenesis, and hypertrophy of esophageal smooth muscles. This remodeling may lead to esophageal rings, stricture, and dysmotility, and manifest as dysphagia, esophageal food impaction, friability of esophageal mucosa, spontaneous mucosal tear, and/or mucosal tear during instrumentation. 9 The current disease paradigm implicates that EoE is a clinicopathologic condition. It is characterized by symptoms suggestive of esophageal dysfunction and is confirmed by the presence of an intense and patchy eosinophilic infiltration (defined as 15 eosinophils per high-power field) and related inflammatory changes in the esophageal epithelium in the absence of other causes of esophageal eosinophilia such as gastroesophageal reflux disease (GERD). 10 Because EoE diagnosis is based in part on histologic evidence of eosinophilic inflammation limited to the esophagus, esophagogastroduodenoscopy (EGD) is required to obtain multiple random esophageal mucosal biopsies. Esophageal biopsy specimens also are required to monitor the disease clinical course and assess response to therapeutic interventions. EGD, however, is an invasive and expensive test. Furthermore, obtaining multiple random biopsy specimens may increase the cumulative risk for procedural complications and can be clinically intensive. Likewise, the traditional approach to pathology processing of esophageal biopsy specimens can be costly, time consuming, and may delay the treatment because it could take a few days for the reports to become available. Taken together, the current approach to detect and monitor EoE has several key limitations and represents a significant barrier toward optimizing care for individuals affected by this enigmatic condition and advancing the field. This is particularly relevant in the pediatric population because children are inherently less amenable to invasive procedures, and suffer from EoE for longer periods of time given its chronicity. 11 These clinical challenges underscore the need for newer modalities that could facilitate early diagnosis of EoE, reduce random biopsy sampling, improve the accuracy and turnaround time of tissue analysis, and provide novel insights into the EoE pathobiology.
Several groups are working enthusiastically toward developing efficient and accurate modalities to improve our ability to detect and monitor EoE. Identifying serologic markers for EoE was one of the earliest undertakings in this direction because blood tests are used routinely to detect and monitor a variety of conditions in clinical practice. The potential of blood markers such as an absolute eosinophil count, and quantification of specific cytokines (such as IL4, IL5, and IL13) and chemokines (such as eotaxin, eosinophil granule protein, and mast cell tryptase) being implicated in the pathogenesis of EoE and microRNAs associated with allergic inflammation has been explored. [12] [13] [14] Although these research efforts have expanded our understanding of the EoE, none of the panels of blood or serum biomarkers have been validated independently or presently are used in the clinical setting.
This perspective provides an overview of conceptually sound and promising approaches as well as emerging techniques ( Table 1) . As illustrated in Figure 1 , for the purposes of this review, we broadly classified a modality as invasive if it involved using instrumentation to physically enter the body, or noninvasive if natural secretions were collected without actually entering the body.
Invasive Modalities

Esophageal Luminal Contents
Mucosal brushings. Direct-vision brush cytology of the esophageal mucosa obtained through the biopsy channel of an endoscope has been used for screening and early detection of esophageal cancers, and its utility in EoE was investigated recently. [13] [14] [15] In 1 study, brushing specimens were smeared onto glass slides, fixed with 95% ethyl alcohol, and stained with H&E. By using a histology threshold of 15 or more eosinophils per high-power field for EoE diagnosis, the cytology sensitivity was 72%, with a specificity of 70% for disease in the distal esophagus. 16 In another study, esophageal brushings were assessed for EPO in a colorimetric assay visually and by spectrophotometric analysis (at 492 nm), and a strong correlation was observed between absorbance units and the peak eosinophil counts in esophageal biopsy specimens. EPO levels were available within an hour, thereby suggesting this approach holds promise as an efficient, accurate, and real-time approach for detecting EoE. It also reduces the procedural risks, cost, and workload associated with collecting esophageal biopsy specimens. 17 The rapid availability of results may allow timely initiation or modification of EoE therapy. The need for an endoscope to administer this test was a limitation. Developing approaches to administer this test via less-invasive approaches might improve its clinical applicability.
Luminal secretions. Investigating physical characteristics and the chemical composition of esophageal luminal secretions offers a unique opportunity to elucidate the esophageal microenvironment and study constituents involved in disease development. It allows representative sampling of a larger surface area of the esophagus, an attribute in a patchy disease such as EoE. Esophageal luminal secretions can be aspirated through the endoscope or sampled via devices such as a cytosponge or a string. The utility of differential cell counts in esophageal aspirates, collected using a bronchoalveolar lavage device adapted to fit the endoscope suction system, to discriminate between GERD, EoE, and controls has been examined. 18 The thin prep of esophageal aspirate from GERD patients showed a predominance of neutrophils, whereas a higher eosinophil count was noted in EoE patients. Interestingly, patients with an inflammatory phenotype of EoE had higher eosinophil counts compared with patients with normal endoscopy or a fibrostenotic phenotype; the eosinophil counts also correlated with an eosinophilic esophagitis endoscopic reference scoring system called EoE Endoscopic Reference Scoring system. 19 A modest correlation was observed between the average numbers of eosinophils in aspirate and in esophageal biopsy specimens.
The collection of esophageal luminal contents and surface epithelial cells using a cytosponge, an indigestible gelatin capsule containing compressed mesh attached to a string, is an emerging approach. This device has been used previously to screen for Barrett's esophagus and esophageal cancer. 20 In a feasibility and implementation study, it was used to collect esophageal luminal secretions from EoE patients. The sensitivity of the eosinophil count in luminal secretions to diagnose EoE was 84.6%, and also had a modest correlation with the maximal number of eosinophils on histology. 21 The esophageal string test (EST) is another stringbased technology, adapted from Enterotest (HDC Corporation, Pilpitas, CA), to collect esophageal luminal secretions. 22 In a proof-of-principle study, the eosinophil-derived proteins, such as MBP1, EDN, eosinophil cationic protein, EPO, and galectin-10, in the esophageal mucosal biopsy specimens correlated with the levels quantified in the luminal secretions captured by the EST, and the panel of luminal biomarkers of eosinophilic inflammation (EoE biomarker panel) significantly correlated with EoE disease activity. These findings support the use of EST as a sensitive test for detecting biochemical changes related to EoE and monitoring therapeutic efficacy in children and adults with EoE. 23 Taken together, emerging modalities based on testing the esophageal luminal secretions have the potential to serve as a relatively less-burdensome alternative approach to diagnose and monitor EoE. Cytosponge and EST may not be suitable in individuals with severe esophageal stricture or remodeling, history of fundoplication, gelatin allergy, or swallowing difficulties. Although these tests generally have been easy to perform and are reported to be well tolerated, more work is needed to improve the safety and develop convenient protocols that can be used in an outpatient clinical setting. For instance, the cytosponge currently is under manufacturer's recall for 2 reports of the sponge detaching during device retrieval and is not yet commercially available. The protocol in the proof-of principle study involved administering EST overnight (12-hour period), and this can be a major limiting factor toward expanding its clinical utility. In an ongoing study, the ability of the EST EoE biomarker panel to monitor therapeutic efficacy in a 1-hour sampling time is being validated. Shortening the time frame to a clinically relevant test period may facilitate its use and potential impact in the outpatient clinic setting.
Visual Methods
EGD remains the mainstay in the management of EoE; therefore, refining current endoscopic approaches and adding new dimensions to existing techniques to improve our ability to detect EoE is an area of intense collaborative research.
Unsedated transnasal endoscopy. Transnasal endoscopy (TNE) has been used in the screening and surveillance of esophageal cancers in outpatient settings without the need for anesthesia or sedation. 24, 25 TNE is gaining attention in the detection and management of EoE. It facilitates endoscopic evaluation of the esophageal and gastric mucosa, and allows obtaining mucosal biopsy specimens from these sites. Initial observations from EoE patients suggest that TNE is safe and cost effective. It appears to be preferred by parents and patients alike when compared with conventional EGD. 26 Although TNE holds promise to impact the way we detect and monitor EoE positively and potentially reduce some of the burden associated with the current approach, certain technical issues remain to be addressed. Because the biopsy forceps used in TNE are relatively smaller (1.2 or 2 mm) compared with the standard 2.8-mm biopsy forceps, the adequacy of esophageal biopsy specimens in terms of depth and surface area needs to be deliberated carefully because the histopathology is crucial to disease management. Performing TNE in EoE patients currently is limited to the research setting and is performed by gastroenterologists trained in technical and cognitive components of TNE. Additional studies to establish the feasibility, safety, acceptability, and cost effectiveness of TNE in the management of EoE may help this modality achieve its full potential.
Biophotonic imaging. The application of light-based technologies to image, detect, and characterize the interplay between light and biological materials, including cells and tissues, is an emerging multidisciplinary research area. The conventional high-resolution white-light endoscopy is used routinely by endoscopists to identify mucosal abnormalities in the esophagus such as rings, linear furrows, and white plaques that can support the diagnosis of EoE, guide biopsy decisions, and assess response to treatment. However, white-light endoscopy provides limited information on changes at the cellular level. Although biophotonic techniques currently are experimental, novel optical designs, miniature scanning mechanisms, and specific probes are being developed to acquire real-time imaging of tissue detail at the cellular level (Figure 2) .
Endomicroscopy enables in vivo imaging of the mucosal layer at very high magnification and resolution, and has been used for in vivo diagnosis of esophageal malignancy. 27 Emerging data have indicated that fluorescein-guided endomicroscopy has the potential to detect histopathologic changes suggestive of EoE and can facilitate an in vivo diagnosis of EoE. 28 Likewise, reflectance confocal endomicroscopy, which measures the confocal images of backscattered light, thus obviating the need for administration of contrast, can count intraepithelial eosinophil load and holds promise to identify microstructural abnormalities associated with EoE. 29 Spectrally encoded confocal microscopy is a highspeed form of reflectance confocal microscopy capable of being miniaturized and can acquire images of microscopic structures without fast mechanical scanning. 30 A tethered confocal endomicroscopy capsule has been used for in vivo visualization of esophageal epithelium in pigs, and has shown promise in identifying eosinophils in ex vivo experiments involving esophageal biopsy specimens obtained from EoE patients. 31 Future studies likely will be aimed at developing the technology such that it could be used in an office setting without sedation and can be configured to obtain microscopic images automatically over the entire esophagus.
Multiphoton microscopy (MPM) is another method to image living cells, especially within intact tissues using a near-infrared light source. The ability to obtain 3-dimensional images with this bioimaging technique is an unprecedented advantage compared with other imaging modalities. MPM also allows increased depth of penetration as compared with confocal microscopy and can be less phototoxic to live specimens. Depending on the power of the light source, the MPM potentially can provide subcellular structural details up to a depth of 300 mm to 1 mm. Furthermore, MPM is sensitive to eosinophil autofluorescence and accurately can identify and quantify the number of eosinophils over an epithelial volume. As a result, MPM can provide greater accuracy and precision for EoE diagnosis and monitoring. MPM has been used to quantify eosinophils in the nasal mucosal smears collected from patients with allergic rhinitis. 32 In an ex vivo study, MPM has been shown to be useful in detecting eosinophils within squamous epithelium, characterize the distribution of eosinophils with depth below the mucosal surface, and quantify the number of eosinophils within a 3-dimensional volume in EoE. 33 Although biophotonic imaging offers potentially exciting modalities to detect and monitor EoE, more work needs to be performed to develop devices that will permit in vivo studies, and allow obtaining an optical biopsy, thereby minimizing the need for collecting esophageal biopsy specimens.
Mucosal impedance. The endoscope-guided mucosal impedance (MI) test using a through-the-scope catheter can investigate mucosal changes, in particular the epithelial permeability to the electrical conduction and the dilated intracellular spaces associated with chronic inflammatory conditions by measuring the conductivity of esophageal epithelium to low-intensity electric current. Dilated intracellular spaces are sensitive but not specific for GERD or EoE, it also has been reported in asymptomatic healthy individuals. 34 The MI pattern potentially can help differentiate between GERD, controls, and EoE patients. Specifically, the MI pattern is consistently low in EoE patients when measured at different sites in the esophagus compared with the gradation noted in GERD patients. In addition, MI in patients with active EoE is significantly lower when compared with patients with inactive EoE, which is similar to that observed in the normal esophagus of controls. These suggest the possibility that in vivo esophageal MI measurement, with attention to technical details, can assess disease activity without the need for esophageal biopsies. 35 Factors limiting direct contact of MI sensors with the esophageal mucosa, such as air and luminal contents, including oropharyngeal secretions and gastroduodenal refluxate, can interfere with MI measurements. An esophageal balloon to push sensors directly to esophageal mucosa has been shown to reduce the interference related to air and luminal secretions. 36 Endoscopic functional luminal imaging probe. The endoscopic functional luminal imaging probe (EndoFLIP; Crospon (USA), Carlsbad CA) uses impedance planimetry to calculate multiple adjacent cross-sectional areas within a cylindric bag while simultaneously measuring intraluminal pressure during controlled volumetric distention. 37, 38 It potentially allows objective assessment of the subepithelial remodeling that is not confined to the muscular function. The device is placed into the esophagus either transnasally, transorally, or endoscopically in a sedated or awake patient. The data obtained from this device requires complex postacquisition processing and specialized programming that is not widely available. Emerging evidence has suggested that the esophageal distensibility (as determined by esophageal crosssectional area) and esophageal compliance (as defined by a change in esophageal volume as a function of intraluminal pressure) are reduced in EoE patients compared with controls. 39 Initial experiences suggest that the EndoFLIP is safe and well tolerated, and is not associated with esophageal bleeding or mucosal tears. It may not have a considerable role in the diagnosis of EoE, but can have important implications in defining EoE phenotypes, assessing severity, tracking disease activity, and therapeutic monitoring. 40 The EndoFLIP increasingly is being used for EoE research in specialized centers. Developing standard protocols to investigate esophageal biomechanics in EoE, systematize data analysis methodology, and gathering data to support its utility in routine clinical practice likely could advance the application of this emerging modality in clinical settings outside of specialized centers in the near future.
Esophageal manometry. High-resolution manometry (HRM) is used to study the esophageal pressure topography, and is used to evaluate esophageal dysmotility in a variety of esophageal diseases. 41 HRM has replaced conventional manometry because of its technical advantages and better reproducibility. 42 In EoE, dysphagia is a common symptom and this might reflect underlying esophageal dysmotility. By using HRM, multiple studies have observed that patients with EoE have variable motility patterns ranging from normal motility to weak and frequent peristalsis in the esophagus. Although these findings are interesting, they overlap with other common esophageal disorders and are neither sensitive nor specific to EoE. Abnormal esophageal pressurization, characterized by panesophageal pressurization and distal esophageal pressurization, appears to be a relatively common finding in EoE patients and is thought to reflect the reduced esophageal compliance secondary to underlying fibrotic transformation and likely disruption of normal esophageal biomechanics. [43] [44] [45] Furthermore, intrabolus pressure measured using HRM has shown modest promise in distinguishing inflammatory from fibrostenosing phenotypes of EoE as classified per the EoE Endoscopic Reference Scoring system. 46 Although HRM may provide an additional avenue to characterize the clinical course and progression of EoE, it appears to have limited utility in detecting incident cases of EoE and differentiating EoE from common confounding esophageal disorders.
Tissue Based Methods
Eosinophilic esophagitis diagnostic panel. The eosinophilic esophagitis diagnostic panel (EDP) is a tissuebased (esophageal biopsy) commercially available test that is highly sensitive and specific for diagnosing EoE. This test examines 94 genes that are expressed differentially in EoE patients. EDP can distinguish active EoE patients from EoE patients in remission and from nonEoE controls such as GERD patients. Notably, it has the potential to identify patients at high risk for EoE based on their inconclusive histologic evaluation. The EDP test can be performed on a single esophageal biopsy. This offers EDP an advantage over the conventional approach wherein per current consensus recommendations multiple esophageal biopsy specimens are required to identify EoE patients. Furthermore, EDP has the potential to provide deeper insight into tissue and EoE genotypes and improve our understanding of the EoE pathobiology. 47 
Noninvasive Modalities
If it were possible to predict EoE or monitor EoE through noninvasive methods, this would allow selective testing for patients most at risk for EoE and also reduce the number of endoscopies. Such an approach also would allow for simple, quick, and cost-effective means of managing EoE patients. With biotechnological advances, there has been increasing interest in evaluating the diagnostic potential of body fluids that can be collected through noninvasive methods. For example, stool EDN has been investigated previously as a potential noninvasive marker of EoE. 48 
Saliva
Because the oronasopharyngeal cavity often serves as the portal of entry for putative culprit antigens in EoE, it is possible that markers of EoE could be reflected in oronasopharyngeal secretions (ie, saliva). Saliva is rich in molecular and microbial analytes, readily available in most patients, and can be collected noninvasively in a few minutes. 49, 50 Preliminary evidence from ongoing studies has indicated that salivary IL4 and IL5 can be increased significantly in children with EoE after controlling for their atopic comorbidities such as allergic rhinitis and asthma, and exposure to medications. MicroRNAs, known to act as diagnostic and prognostic markers of systemic diseases, can be expressed similarly in saliva as in serum. Pilot studies also have indicated massive dysregulation of salivary microRNAome in EoE when compared with healthy controls, with the potential to serve as noninvasive markers for identifying and monitoring response to treatment in EoE.
51-53
Exhaled Nitric Oxide
Exhaled nitric oxide has been examined as a noninvasive marker of airway inflammation. In a proofof-concept study, normal levels of exhaled nitric oxide had good specificity for screening children with EoE without airway inflammation. 54 Another study showed a modest but statistically significant reduction in exhaled nitric oxide in EoE patients who responded to swallowed topical steroids, 55 suggesting that fractionated exhaled nitric oxide could serve as a useful measure of disease activity.
Urine
In a proof-of-concept study, 3-bromotyrosine, a chemical marker of eosinophil activation in urine samples, was 93-fold higher in EoE patients compared with nonatopic controls, and 13-fold higher in EoE patients compared with atopic controls. Overall, the specificity and negative predictive value of urine 3-bromotyrosine to identify EoE correctly appears to be encouraging in both nonatopic patients and in patients with other atopy. 56 
Conclusions
In a relatively short period of time, EoE has evolved from a somewhat unknown entity to a burdensome clinicopathologic condition. Recommended invasive, cumbersome, and expensive approaches to diagnose and monitor disease activity represent a significant barrier toward advancing care of individuals affected by this enigmatic condition. Advances in the use of currently available and novel technologies holds promise in making the diagnosis, and monitoring, of EoE accurate, efficient, timely, convenient, and cost effective.
